Nuvation Bio Inc (NUVB)vsVertex Pharmaceuticals Inc (VRTX)
NUVB
Nuvation Bio Inc
$6.59
-1.49%
HEALTHCARE · Cap: $2.18B
VRTX
Vertex Pharmaceuticals Inc
$483.33
-1.44%
HEALTHCARE · Cap: $119.94B
Smart Verdict
WallStSmart Research — data-driven comparison
Vertex Pharmaceuticals Inc generates 8441% more annual revenue ($12.22B vs $143.05M). VRTX leads profitability with a 35.5% profit margin vs -102.1%. VRTX earns a higher WallStSmart Score of 68/100 (B-).
NUVB
Avoid29
out of 100
Grade: F
VRTX
Strong Buy68
out of 100
Grade: B-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for NUVB.
Margin of Safety
+49.1%
Fair Value
$941.26
Current Price
$483.33
$457.93 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Revenue surging 2599.0% year-over-year
Conservative balance sheet, low leverage
Keeps 36 of every $100 in revenue as profit
Strong operational efficiency at 38.1%
Earnings expanding 61.4% YoY
Safe zone — low bankruptcy risk
Large-cap with strong market position
Every $100 of equity generates 22 in profit
Areas to Watch
0.0% earnings growth
Operating margin of 4.7%
ROE of -45.7% — below average capital efficiency
Distress zone — elevated risk
Expensive relative to growth rate
Moderate valuation
Weak financial health signals
Comparative Analysis Report
WallStSmart ResearchBull Case : NUVB
The strongest argument for NUVB centers on Revenue Growth, Debt/Equity. Revenue growth of 2599.0% demonstrates continued momentum.
Bull Case : VRTX
The strongest argument for VRTX centers on Profit Margin, Operating Margin, EPS Growth. Profitability is solid with margins at 35.5% and operating margin at 38.1%.
Bear Case : NUVB
The primary concerns for NUVB are EPS Growth, Operating Margin, Return on Equity.
Bear Case : VRTX
The primary concerns for VRTX are PEG Ratio, P/E Ratio, Piotroski F-Score.
Key Dynamics to Monitor
NUVB profiles as a hypergrowth stock while VRTX is a mature play — different risk/reward profiles.
NUVB carries more volatility with a beta of 1.53 — expect wider price swings.
NUVB is growing revenue faster at 2599.0% — sustainability is the question.
VRTX generates stronger free cash flow (1.3B), providing more financial flexibility.
Bottom Line
VRTX scores higher overall (68/100 vs 29/100), backed by strong 35.5% margins. Both earn "Strong Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Nuvation Bio Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Nuvation Bio Inc., a clinical-stage biopharmaceutical company, is focused on developing therapeutic candidates for oncology. The company is headquartered in New York, New York.
Visit Website →Vertex Pharmaceuticals Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Vertex Pharmaceuticals, Inc. is an American biopharmaceutical company based in Boston, Massachusetts.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?